Vancomycin loading doses: a systematic review

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Infectious Diseases

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive infections.
• Achieving therapeutic vancomycin trough concentrations (15-20 mg/L) is crucial for efficacy and minimizing resistance.
• The role of vancomycin loading doses (LDs) in optimizing pharmacokinetic and pharmacodynamic profiles requires systematic evaluation.

Purpose of the Study:

• To systematically review the literature on the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of vancomycin loading doses (LDs).
• To assess the evidence supporting the use of vancomycin LDs for achieving target therapeutic concentrations.

Main Methods:

• A comprehensive literature search was conducted across multiple databases (MEDLINE, EMBASE, Cochrane, etc.) and clinical trial registries.
• Included studies focused on vancomycin LDs aiming for trough concentrations of 15-20 mg/L.
• Exclusion criteria included nonhuman, non-English, oral vancomycin, and dialysis patient studies; study quality was assessed using the USPSTF 1996 classification.

Main Results:

• Eight studies (5 manuscripts, 3 abstracts) met the inclusion criteria.
• Four of six adult studies indicated that vancomycin LDs significantly increased the proportion of patients achieving target trough concentrations.
• Studies in pediatric populations did not demonstrate rapid attainment of vancomycin levels ≥15 mg/L with LDs; no studies assessed clinical or microbiological outcomes.

Conclusions:

• High-quality evidence supporting the use of vancomycin LDs is currently lacking.
• Vancomycin LDs may facilitate faster achievement of target trough concentrations in adults, but data for pediatric, obese, and renally impaired patients are limited.
• Further research is essential to determine the impact of vancomycin LDs on clinical and microbiological outcomes.